usp5

USP5-IN-1 (compound 64) is a potent deubiquitinase USP5 inhibitor that binds to the USP5 ZnF-UBD with a KD of 2.8 μM and is selective over nine proteins containing structurally similar ZnF-UBD domains. Additionally, USP5-IN-1 inhibits the USP5 catalytic cleavage of a di-ubiquitin substrate [1].

EOAI3402143 inhibits Usp9x and Usp24 activity, increases tumor cell apoptosis. EOAI3402143 phenocopies the FAS induction and apoptotic sensitization of Usp5 knockdown and fully blocks melanoma tumor growth.

P 22077 (P22077) is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM. It also inhibits the closely related USP47.

IU1-47 is an effective and specific USP14 inhibitor (IC50: 0.6 μM). IU1-47 causes tau elimination in cultured neurons. IU1-47 inhibits IsoT/USP5 (IC50: 20 μM).

WCY-8-67 TFA is an orally bioavailable selective USP5 inhibitor with an IC₅₀ of 1.33 μM. It induces apoptosis in vitro and inhibits the JAK/STAT3 and PI3K/AKT signaling pathways. WCY-8-67 TFA suppresses the proliferation of AE-positive acute myeloid leukemia (AML) cells, induces G1 phase cell cycle arrest, and promotes cell differentiation. It shows significant anti-leukemic activity in mouse in vivo experiments and can be used in AML research.

Cysteine protease inhibitor 2 is a cysteine protease inhibitor. Cysteine protease inhibitor 2 inhibited DCT116 and PC3 cells with GI50 values of 6.5 μM and 4.4 μM, respectively.

Vialinin A (Terrestrin A), a p-terphenyl compound, exhibits antioxidant properties and acts as a potent inhibitor of TNF-α, USP4, USP5, and sentrin/SUMO-specific protease 1 (SENP1). Its efficacy in autoimmune diseases and cancer research is noteworthy, highlighting its potential therapeutic applications.

Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

UBTR008295a is USP5 Inhibitor.